Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY10 | O00398 | 9/20 | 0.35 |
| ▸ | GPR174 | Q9BXC1 | 5/20 | 0.35 |
| ▸ | GPR34 | Q9UPC5 | 4/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.34 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.34 |
| ▸ | FABP3 | P05413 | 1/20 | 0.33 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.33 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.33 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.33 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25657141 | 0.84 | TSHR (0.33) | P2RY10GPR174GPR34FABP3TSHR | |
| SCHEMBL269622 | 0.80 | CYP3A4 (0.38) | TSHR | |
| SCHEMBL25020371 | 0.79 | BTN3A1 (0.44) | TSHR | |
| SCHEMBL25657140 | 0.79 | FAP (0.33) | LPAR1LPAR3TSHR | |
| SCHEMBL11758345 | 0.78 | CYP3A4 (0.37) | TSHR | |
| SCHEMBL1396965 | 0.78 | CYP3A4 (0.37) | TSHR | |
| SCHEMBL16119749 | 0.77 | PLA2G2A (0.36) | ENPP2TSHR | |
| SCHEMBL25657143 | 0.77 | TSHR (0.40) | TSHR | |
| SCHEMBL18006575 | 0.76 | PLA2G2A (0.39) | — | |
| SCHEMBL5665027 | 0.74 | LPAR3 (0.40) | LPAR1LPAR3LPAR6LPAR4LPAR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151024-A1 | STING AGONISTIC COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230141284-A1 | CANCER THERAPEUTIC METHOD | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141284-A1 | CANCER THERAPEUTIC METHOD | STING1, CGAS, IFNAR1 | P2RY10 234/4885GPR174 102/4885GPR34 118/4885 |
| US-20230151024-A1 | STING AGONISTIC COMPOUND | STING1, CGAS, TLR1 | P2RY10 54/4885GPR174 66/4885GPR34 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.